Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 19/20 | 0.63 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | BRD2 | P25440 | 2/20 | 0.51 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17798161 | 1.00 | BRD4 (0.63) | BRD4EPHX2BRD2CREBBPBRD3 | |
| SCHEMBL17797960 | 0.79 | BRD4 (0.79) | BRD4CREBBP | |
| SCHEMBL29920564 | 0.79 | BRD4 (0.79) | BRD4CREBBP | |
| SCHEMBL17797962 | 0.79 | BRD4 (0.79) | BRD4CREBBP | |
| SCHEMBL29920528 | 0.77 | EPHX2 (0.56) | BRD4EPHX2CREBBP | |
| SCHEMBL17798058 | 0.77 | EPHX2 (0.56) | BRD4EPHX2CREBBP | |
| SCHEMBL6541692 | 0.75 | EPHX2 (0.62) | EPHX2 | |
| SCHEMBL1884654 | 0.74 | CYP11B1 (0.65) | BRD4EPHX2 | |
| SCHEMBL29920791 | 0.74 | BRD4 (0.54) | BRD4BRD2CREBBPBRD3BRDT | |
| SCHEMBL17798011 | 0.74 | BRD4 (0.54) | BRD4BRD2CREBBPBRD3BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11446306-B2 | Bicyclic bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885EPHX2 2831/4885BRD2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.